Literature DB >> 2549610

Bacterial resistance to quinolones: mechanisms and clinical importance.

J S Wolfson1, D C Hooper.   

Abstract

An overview of bacterial resistance to new quinolones is presented with a consideration of mechanisms, clinical importance, and approaches to suppression of the emergence of resistance. Single-step mutation to high-level resistance occurs at a frequency of less than or equal to 10(-10) for many bacterial species but can be readily selected by serial exposure of cells to increasing drug concentrations. Two mechanisms of resistance have been identified: alteration in the target enzyme DNA gyrase and decreased drug permeation. Emergence of resistance to clinically useful quinolones thus far has been uncommon. Superinfection has been documented but also has been uncommon. Emergence of resistance appears to occur more often with certain bacterial species, including Pseudomonas aeruginosa and Staphylococcus aureus. In the special setting of cystic fibrosis, patients with P. aeruginosa infections often respond favorably despite emergence of resistance. Methods to minimize the emergence of quinolone resistance should be evaluated in an effort to preserve the clinical utility of these drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549610     DOI: 10.1093/clinids/11.supplement_5.s960

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  36 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.

Authors:  J Pace; A Bertasso; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.

Authors:  M G van Kraaij; A W Dekker; E Peters; A Fluit; L F Verdonck; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

5.  In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.

Authors:  N Masuda; Y Takahashi; M Otsuki; E Ibuki; H Miyoshi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

7.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus.

Authors:  C J Soussy; J S Wolfson; E Y Ng; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Authors:  C R Marchbanks; J R McKiel; D H Gilbert; N J Robillard; B Painter; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 10.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.